Generic user fees could boost FDA inspection powers
News | 22 August 2011
Generic drugmakers have forged a tentative deal with the US government that could see user fees being used to help the FDA inspect overseas active pharmaceutical ingredient manufacturing plants. The proposal could see almost $300 million in additional ...
Click on the link to read the full article at InPharm
(This link will open in a new window)
- Elan makes "transformational" acquisitions and a divestment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
